CVS Health (CVS)
(Delayed Data from NYSE)
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
Zacks News
Factors Setting the Stage for Fred's (FRED) in Q4 Earnings
by Zacks Equity Research
Fred's (FRED) has been reeling under soft comparable store sales for quite some time now. Let's see if Fred???s strategic initiatives can provide any respite in Q4.
Can Strategic Efforts Aid Fred's to Achieve a Turnaround?
by Zacks Equity Research
Fred's (FRED) focuses on pharmacy organization and expense reduction to achieve turnaround. However, receding comps continue to hurt.
Cigna to Take Over Express Scripts (ESRX) for $67 Billion
by Zacks Equity Research
Per a definitive agreement, Cigna will take over Express Scripts (ESRX) in a cash-and-stock transaction worth $67 billion.
Why Is CVS Health Corporation (CVS) Down -9.2% Since its Last Earnings Report?
by Zacks Equity Research
CVS reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Pharmacy Services Aid CVS Health, Aetna Deal an Upside Too
by Zacks Equity Research
CVS Health (CVS) is likely to earn $750 million from near-term synergies after the completion of Aetna acquisition deal.
Walgreens (WBA) May Buy Remaining Stake in AmerisourceBergen
by Zacks Equity Research
Walgreens' (WBA) rumored buyout claim over the remaining stake in AmerisourceBergen comes close on the heels of its rival CVS Health's hefty $69-billion worth acquisition of health insurer, Aetna.
Top Analyst Reports for Broadcom, Canadian National & CVS Health
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Broadcom (AVGO), Canadian National (CNI) and CVS Health (CVS).
CVS Health (CVS) Beats On Q4 Earnings & Revenues Estimates
by Zacks Equity Research
CVS Health (CVS) rides high on strength in Pharmacy Services segment in Q4.
Health Insurance Stock Outlook - January 2018
by Zacks Equity Research
Rapid evolution is being witnessed in the health insurance industry as the players are taking concerted efforts to transform themselves into comprehensive health care providers from their earlier role of traditional payers.
Fred's (FRED) Sluggish Store Sales Keep Investors at Bay
by Zacks Equity Research
Fred's (FRED) continues to witness dismal comps and store closures. Also, cancelled dividend and merger deal make this retailer a less-favored pick.
5 Reasons Why McKesson Deserves a Place in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to pursue deals, divestitures and acquisitions to drive growth. The company's impressive performance in 2017 accounts for its potential to sustain the momentum.
Company News For January 5, 2018
by Zacks Equity Research
Companies In The News are:
CVS Health's (CVS) Outlook for 2018 Cheered by Investors
by Zacks Equity Research
CVS Health (CVS) to witness increased cash flow of around $1.2 billion in 2018, courtesy the latest US Tax legislation.
Fred's Tanks 79% in a Year: Any Chances of Revival Ahead?
by Zacks Equity Research
Fred's (FRED) has been struggling with its dismal comps performance stemming from receding traffic and store closures. Also, management cancelled its quarterly dividend recently.
Declining Comps Likely to Hurt Fred's (FRED) in Q3 Earnings
by Zacks Equity Research
Fred's (FRED) third-quarter fiscal 2017 performance is expected to be hurt by dismal comps trend.
Company News For Nov 7, 2017
by Zacks Equity Research
Companies In The News are: ON,BRK.B,S,TMUS,CVS
McKesson (MCK) to Acquire RxCrossroads for $735 Million
by Zacks Equity Research
McKesson's (MCK) acquisition of RxCrossroads will boost its Specialty Health business.
CVS Health (CVS) Beats On Q3 Earnings, Revenues In Line
by Zacks Equity Research
CVS Health (CVS) witnesses year over year growth in Pharmacy Services segment in Q3.
Is a CVS Health (CVS) - Aetna (AET) Deal in the Cards?
by Arpita Dutt
Is an e-commerce company's interest in entering the drug pharmacy space the reason behind CVS Health's (CVS) interest in acquiring Aetna?
Rite Aid (RAD) Slumps 14% Since Q2 Loss: What Lies Ahead?
by Zacks Equity Research
Rite Aid Corporation (RAD), which had quite an eventful journey of late, reported dismal second-quarter fiscal 2018 results last week. However, latest deal with Walgreens should benefit.
Can Fred's Strategies Help It Counter Slow Comps & Traffic?
by Zacks Equity Research
Fred's (FRED) has been struggling with declining store traffic and sluggish comps over the past few quarters. The company has been focusing on cost reduction and internal restructuring.
What FTC's Curtail on RAD Store Purchase Means for Walgreens?
by Zacks Equity Research
Walgreens' (WBA) purchase of lesser number of Rite Aid stores upsets investors. Let's draw an insight from this.
Rite Aid Gets FTC Nod for Sale of Fewer Stores to Walgreens
by Zacks Equity Research
After four amendments, Rite Aid Corp. (RAD) and Walgreens Boots Alliance Inc. (WBA) finally received a nod for the fresh proposal the latter put forward yesterday.
Why Did Rite Aid (RAD) Stock Crash Today?
by Ryan McQueeney
Shares of Rite Aid (RAD) fell more than 10% on Tuesday after Walgreens Boots (WBA) received government approval to buy fewer Rite Aid stores than had initially been proposed.
Walgreens to Revisit Rite Aid Deal for Antitrust Approval
by Zacks Equity Research
The Federal Trade Commission ("FTC") seems to be getting harsher on drugstore chains Walgreens Boots Alliance Inc. (WBA) and Rite Aid Corp. (RAD), which have been trying to appease the regulatory body since its initial merger pact in 2015.